2027 EQA Catalogue

2027 EQA Catalogue launch

EMQN is delighted to launch its 2027 EQA Catalogue, featuring an expanded portfolio of external quality assessment schemes designed to support laboratories across a wide range of genomic and molecular diagnostic disciplines.

This year’s catalogue introduces our new Haemato-Oncology category, alongside new EQA schemes for Newborn Screening, Neurofibromatosis, and MT-RNR1 testing (Pharmacogenetics). It also includes updates to existing programmes, enhanced offerings, and new opportunities for participation, reflecting our ongoing commitment to providing high-quality, clinically relevant EQA services that meet the evolving needs of the global laboratory community.

New EQA Haemato-Oncology Category

Discover our new EQA schemes for molecular haemato-oncology, designed to evaluate both analytical performance and clinical interpretation.

Find out more

New Reproductive and Postnatal Genomics

New Newborn Screening EQA Evaluate genomic newborn screening performance with clinically realistic samples for SMA, CFTR and PKU, plus an optional panel testing challenge.

Find out more

New Genomic and Inherited disorders schemes

New Neurofibromatosis and Epigenetic Signatures EQA Schemes Supporting quality and confidence in advanced genomic diagnostics through independent assessment and educational feedback.

Find out more

Pharmacogenetics Category

Assess analytical performance and clinical interpretation of key MT-RNR1 variants associated with aminoglycoside-induced hearing loss through our new pharmacogenomics EQA pilot.

Find out more

New EQA Catalogue

Find the right EQA schemes for your laboratory and start planning your participation for 2027.

Download now

The EQA Launch Webinar is Now Available to Watch.

Thank you to everyone who joined our EQA launch webinar. If you couldn’t attend, or would like to revisit the key announcements, the full recording is now available.